PT-141 (Bremelanotide) is a melanocortin-family reference peptide evaluated for its role in neural receptor signaling, MC3R/MC4R activation, and hypothalamic pathway modulation. It is provided as a lyophilized research material for controlled analytical, laboratory, and educational applications relating to neuroendocrine peptide modeling.

Research Overview

PT-141 is studied for its ability to act as a melanocortin receptor agonist—specifically targeting MC3R and MC4R receptor sites in central nervous system analog models. It has been referenced in published literature for its role in arousal-linked hypothalamic signaling, neural activation timing, and peptide-response kinetics distinct from peripheral vasodilatory mechanisms.

Key Research Points

• Evaluated for MC3R/MC4R receptor agonism and related neurochemical signaling
• Distinct neural pathway activation separate from PDE5-linked vasodilatory response
• Observed dose-dependent receptor engagement in controlled trial conditions
• Included in neuroendocrine receptor-mapping and peptide-kinetic research

Observed Outcomes in Research

• CNS activation: Dose-dependent increases in hypothalamic activity observed in imaging studies (Bremelanotide Phase II/III data, 2005–2019)
• Arousal-related signaling: Elevated melanocortin pathway activation associated with pre-optic and limbic regions under controlled dosing
• Latency of response: Measurable neural receptor activation typically within 30–90 minutes post-administration
• Duration window: 4–8 hours of measurable receptor activity before baseline return
• Tolerability (in literature): Mild nausea, transient flushing, and localized erythema noted during early dose-escalation trials

These outcomes reflect controlled research data and do not constitute therapeutic claims or guidance for human application.

Reference Sampling & Handling

• Form: Lyophilized peptide powder
• Strength: 10 mg per vial
• Reconstitution: 2 mL sterile bacteriostatic water → 5 mg/mL
• Storage: 2–8 °C after reconstitution

Reference Sampling Table (2 mL → 5 mg/mL)

Reference calculations based on 2 mL reconstitution (5 mg/mL). 1 unit = 0.01 mL ≈ 50 µg.

Reference Frequency & Safety Notes

• Recommended reference interval: Do not exceed 1 observation per 24 hours.
• Observed upper limit: ≤ 8 reference samples per 30-day period in published data.
• Peak signal window: Receptor activation observed 45 – 90 minutes post-sample.
• Reset period: ≥ 24 hours between successive sampling for receptor washout consistency.
• Do not exceed reference range: 2.5 mg (50 units / 0.50 mL) per 24-hour interval.

These limits reflect dose-frequency parameters reported in Phase III Bremelanotide clinical trials and are provided solely for laboratory consistency and analytical planning.

Reference Sampling Formula

Units = Desired mg × 20  (e.g., 1 mg = 20 units at 5 mg/mL)

Comparative Research Applications

• Melanocortin receptor signaling and binding-curve analysis
• Peptide SAR and neurochemical response mapping
• Cross-receptor MC3R / MC4R studies under time-dependent assay conditions
• Reconstitution stability and solubility kinetics

What’s in the Box

• 1 × PT-141 10 mg lyophilized peptide vial
• 1 × 2 mL sterile bacteriostatic water vial

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals supplies purity-verified peptides for analytical, educational, and laboratory research. Every lot undergoes identity confirmation and concentration verification to ensure consistent, reproducible data generation.

For laboratory, educational, and research use only. Not for human or veterinary ingestion, application, or therapeutic use. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and compliance with applicable regulations.